Advancing new drug development with AI
The article focused on how Insilico Medicine is accelerating the drug development process using artificial intelligence. They managed to reduce the screening time to approximately one year instead of four and a half years by integrating AI technologies with laboratory research in China. The article also explains that the program typically reaches the screening stage after testing between 60 and 200 molecules, and that since 2021, the company has launched 31 candidates, 13 of which have received trial drug licenses. Additionally, the article highlights that AI speeds up target identification and drug design, though clinical trials and manufacturing are still necessary. This technology has contributed to shortening the drug development timeline in China by nearly two years compared to Western markets. It is noted that the third phase of trials for the drug Rintasertib, used to treat pulmonary fibrosis, was designed using AI and involves 320 patients in China to demonstrate its effectiveness after successful earlier phases.
Notice: This Is an AI-Generated Summary
Comments (0)